标题
PARP inhibitors: the journey from research hypothesis to clinical approval
作者
关键词
-
出版物
Personalized Medicine
Volume 12, Issue 2, Pages 139-154
出版商
Future Medicine Ltd
发表日期
2015-03-23
DOI
10.2217/pme.14.71
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
- (2015) Kyungsoo Ha et al. Oncotarget
- Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
- (2014) Aki Miyasaka et al. BMC CANCER
- Intraoperative assessment of margins in breast conserving therapy: A systematic review
- (2014) Kerryn Butler-Henderson et al. BREAST
- Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
- (2014) S. K. Gupta et al. CLINICAL CANCER RESEARCH
- Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
- (2014) K. A. T. Naipal et al. CLINICAL CANCER RESEARCH
- ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
- (2014) Young Choi et al. CURRENT PHARMACEUTICAL DESIGN
- Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
- (2014) Panagiotis A. Konstantinopoulos et al. GYNECOLOGIC ONCOLOGY
- Exploration of MR-guided head and neck hyperthermia by phantom testing of a modified prototype applicator for use with proton resonance frequency shift thermometry
- (2014) Wouter C.M. Numan et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Heat exposure enhances radiosensitivity by depressing DNA-PK kinase activity during double strand break repair
- (2014) Makoto Ihara et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- PARP Inhibitors as P-glyoprotein Substrates
- (2014) Denise Lawlor et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Downfall of Iniparib: A PARP Inhibitor That Doesn't Inhibit PARP After All
- (2014) G. Sinha JNCI-Journal of the National Cancer Institute
- A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†
- (2014) Jack M. Su et al. NEURO-ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
- (2013) Kahlin Cheung-Ong et al. CHEMISTRY & BIOLOGY
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Identification of miRNA modulators to PARP inhibitor response
- (2013) Sari Neijenhuis et al. DNA REPAIR
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
- (2013) Joyce F. Liu et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery
- (2013) Nigel Bundred et al. INVESTIGATIONAL NEW DRUGS
- BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells
- (2013) David A. Grotsky et al. JOURNAL OF CELL BIOLOGY
- Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues
- (2013) Moritz Birkelbach et al. Journal of Thoracic Oncology
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
- (2013) A. Min et al. MOLECULAR CANCER THERAPEUTICS
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
- (2013) M. L. Bailey et al. MOLECULAR CANCER THERAPEUTICS
- RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
- (2013) J. Ross Chapman et al. MOLECULAR CELL
- JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1–mediated chromatin response to DNA breaks
- (2013) Sugiko Watanabe et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
- (2013) S Postel-Vinay et al. ONCOGENE
- Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling
- (2013) Martin J. Larsen et al. PLoS One
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure
- (2013) A.M. Kukiełka et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells
- (2013) Fengfeng Cai et al. TUMOR BIOLOGY
- BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas
- (2012) Karuna Garg et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
- (2012) Anneleen Daemen et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
- (2012) E Dean et al. BRITISH JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1
- (2012) S. Nakada et al. CANCER RESEARCH
- Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
- (2012) A. Mukhopadhyay et al. CANCER RESEARCH
- Predicting PARP inhibitor sensitivity and resistance
- (2012) D. Gwyn Bebb et al. CELL CYCLE
- Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
- (2012) Lenka Oplustilova et al. CELL CYCLE
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining
- (2012) Judith W.J. Bergs et al. DNA REPAIR
- BRCA1epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
- (2012) Olafur A. Stefansson et al. Epigenetics
- 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes
- (2012) Kathryn P. Pennington et al. GYNECOLOGIC ONCOLOGY
- Hyperthermia inhibits homologous recombination repair and sensitizes cells to ionizing radiation in a time- and temperature-dependent manner
- (2012) Stefan C. Genet et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells
- (2012) D. Minami et al. MOLECULAR CANCER RESEARCH
- BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair
- (2012) Samuel F. Bunting et al. MOLECULAR CELL
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
- (2011) O A Khan et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
- (2011) Davide Torti et al. EMBO Molecular Medicine
- Regulation of Rad51 function by phosphorylation
- (2011) Sonja Flott et al. EMBO REPORTS
- Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
- (2011) Jens Samol et al. INVESTIGATIONAL NEW DRUGS
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition
- (2011) P. M. Krawczyk et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability
- (2011) A. Aly et al. Journal of Molecular Cell Biology
- Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
- (2010) P. Gottipati et al. CANCER RESEARCH
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors
- (2010) Jurgen Veeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
- (2010) K. J. Dedes et al. Science Translational Medicine
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency
- (2009) Liu Cao et al. MOLECULAR CELL
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
- (2008) E. M. Swisher et al. CANCER RESEARCH
- Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
- (2008) Yolanda Madarnas et al. CANCER TREATMENT REVIEWS
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Modeling therapy resistance in genetically engineered mouse cancer models
- (2008) S ROTTENBERG et al. DRUG RESISTANCE UPDATES
- DNA Damage Responses: Mechanisms and Roles in Human Disease: 2007 G.H.A. Clowes Memorial Award Lecture
- (2008) M. B. Kastan MOLECULAR CANCER RESEARCH
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started